{"entity":{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","aka":[],"tldr":"Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies.","summary":"Reinhard Dummer was principal investigator of COLUMBUS, which established encorafenib plus binimetinib in BRAF-mutant melanoma, and led the first randomised neoadjuvant trial of the oncolytic virus talimogene laherparepvec. He has led ESMO melanoma guidelines and trials in cutaneous T-cell lymphoma and Merkel cell carcinoma, and heads the skin cancer centre at University Hospital Zurich.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D%20melanoma%20encorafenib%20OR%20talimogene"}],"tags":["melanoma","targeted-therapy","switzerland"],"related":[],"cancers":["melanoma","merkel-cell-carcinoma"],"sections":[],"technologies":["kinase-inhibitors","oncolytic-virus"],"targets":["braf"],"drugs":["encorafenib","talimogene-laherparepvec"],"companies":[],"institutions":["usz-zurich"],"pathways":[],"terms":[],"trials":["columbus"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Dermatology and Vice Chairman, Department of Dermatology, University Hospital Zurich","institutionId":"usz-zurich","specialisms":["Melanoma","BRAF/MEK targeted therapy","Oncolytic virus therapy","Cutaneous lymphoma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D%20melanoma%20encorafenib%20OR%20talimogene"}],"papers":[{"title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS)","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(18)30497-2"},{"title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","journal":"Nature Medicine","year":2021,"doi":"10.1038/s41591-021-01510-7"}]},"route":"/people/reinhard-dummer/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"}],"drug":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/"}],"institution":[{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/"}],"trial":[{"id":"bolt","kind":"trial","name":"BOLT","route":"/trials/bolt/"},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/"},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/"}]}}